The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the decay characteristics of HIV in the blood of
patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV
drug, an integrase inhibitor. This study explores how this new combination of therapy reduces
virus in various compartments of the body and immune system.